ZACHARY MATHEWS: Open Payments
NPI 1457048472 · CUMBERLAND, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,762 in 143 payments from 18 companies in 2025. Trend: 2023 $1,717 · 2024 $2,336 · 2025 $2,762
Food & beverage: $2,762
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $572 |
| AstraZeneca Pharmaceuticals LP | 25 | $538 |
| Novo Nordisk Inc | 9 | $219 |
| Amgen Inc. | 10 | $209 |
| PFIZER INC. | 11 | $162 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $122 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $109 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $99 |
| Novartis Pharmaceuticals Corporation | 4 | $93 |
Products named: AIRSUPRA, UBRELVY, VRAYLAR, QULIPTA, BREZTRI, Kerendia, CAPLYTA, NURTEC ODT.
Industry payments across MD — which companies pay providers there.
